SK282452B6 - Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit - Google Patents

Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit Download PDF

Info

Publication number
SK282452B6
SK282452B6 SK892-95A SK89295A SK282452B6 SK 282452 B6 SK282452 B6 SK 282452B6 SK 89295 A SK89295 A SK 89295A SK 282452 B6 SK282452 B6 SK 282452B6
Authority
SK
Slovakia
Prior art keywords
temozolomide
atase
benzylguanine
treatment
pharmaceutical composition
Prior art date
Application number
SK892-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK89295A3 (en
Inventor
John Colin Baer
Azadeh Alison Freeman
Edward Stuart Newlands
Amanda Jean Watson
Joseph Anthony Rafferty
Geoffrey Paul Margison
Original Assignee
Cancer Research Campaign Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Limited filed Critical Cancer Research Campaign Technology Limited
Publication of SK89295A3 publication Critical patent/SK89295A3/sk
Publication of SK282452B6 publication Critical patent/SK282452B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SK892-95A 1993-01-14 1994-01-13 Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit SK282452B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US475493A 1993-01-14 1993-01-14
PCT/GB1994/000065 WO1994015615A1 (en) 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells

Publications (2)

Publication Number Publication Date
SK89295A3 SK89295A3 (en) 1996-06-05
SK282452B6 true SK282452B6 (sk) 2002-02-05

Family

ID=21712364

Family Applications (1)

Application Number Title Priority Date Filing Date
SK892-95A SK282452B6 (sk) 1993-01-14 1994-01-13 Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit

Country Status (20)

Country Link
EP (2) EP0679086A1 (cs)
JP (1) JPH08505615A (cs)
KR (1) KR100352046B1 (cs)
CN (1) CN1277541C (cs)
AU (1) AU5838494A (cs)
CA (1) CA2153775C (cs)
CZ (1) CZ286550B6 (cs)
FI (1) FI953423A7 (cs)
HU (1) HUT72665A (cs)
IL (1) IL108328A (cs)
MX (1) MX9400434A (cs)
MY (1) MY116474A (cs)
NO (1) NO952781L (cs)
PL (1) PL175842B1 (cs)
RU (1) RU2148401C1 (cs)
SK (1) SK282452B6 (cs)
TW (1) TW414710B (cs)
UA (1) UA29466C2 (cs)
WO (1) WO1994015615A1 (cs)
ZA (1) ZA94248B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
AU2021700A (en) * 1998-12-07 2000-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
DE60321450D1 (de) * 2002-02-22 2008-07-17 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
ES2341767T3 (es) * 2002-05-31 2010-06-28 Transmolecular, Inc. Quimioterapia de combinacion con clorotoxina.
CN100366249C (zh) * 2002-09-29 2008-02-06 天津帝士力投资控股集团有限公司 一种替莫唑胺控释给药系统
CN1752088A (zh) * 2004-09-22 2006-03-29 天津市金士力药物研究开发有限公司 含有替莫唑胺酯的药用组合物
CN100431605C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100402091C (zh) * 2005-02-03 2008-07-16 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
CN100350974C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
RU2318509C2 (ru) * 2006-02-10 2008-03-10 Всеволод Иванович Киселев Твердая лекарственная форма дииндолилметана для лечения неопластических заболеваний
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
US8227439B2 (en) 2008-05-15 2012-07-24 Morphotek, Inc. Treatment of metastatic tumors
JP5858932B2 (ja) 2010-02-04 2016-02-10 モルフォテック, インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
CN103169664B (zh) * 2011-12-25 2015-04-22 复旦大学 一种rgd肽修饰的双层载药纳米粒及其制备方法
US20150316536A1 (en) 2012-12-10 2015-11-05 Fred Hutchinson Cancer Research Center Methods for screening
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352669A (en) * 1990-03-13 1994-10-04 The Of The United States Of America As Represented By The Department Of Health And Human Services O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity

Also Published As

Publication number Publication date
CZ179795A3 (en) 1996-04-17
PL309915A1 (en) 1995-11-13
CN1277541C (zh) 2006-10-04
KR100352046B1 (ko) 2003-09-03
MX9400434A (es) 1994-07-29
EP0922458A1 (en) 1999-06-16
SK89295A3 (en) 1996-06-05
CZ286550B6 (cs) 2000-05-17
TW414710B (en) 2000-12-11
CA2153775C (en) 2000-11-14
WO1994015615A1 (en) 1994-07-21
CA2153775A1 (en) 1994-07-21
IL108328A (en) 2010-05-31
ZA94248B (en) 1994-07-13
UA29466C2 (uk) 2000-11-15
FI953423A0 (fi) 1995-07-13
JPH08505615A (ja) 1996-06-18
RU2148401C1 (ru) 2000-05-10
MY116474A (en) 2004-02-28
FI953423L (fi) 1995-08-23
AU5838494A (en) 1994-08-15
PL175842B1 (pl) 1999-02-26
KR960700063A (ko) 1996-01-19
HUT72665A (en) 1996-05-28
FI953423A7 (fi) 1995-08-23
IL108328A0 (en) 1994-04-12
HU9502117D0 (en) 1995-09-28
NO952781L (no) 1995-09-13
CN1117711A (zh) 1996-02-28
NO952781D0 (no) 1995-07-13
EP0679086A1 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
SK282452B6 (sk) Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit
Ishikawa et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
US6552059B2 (en) Pharmaceutical composition for and method of treating leukemia
AU714057B2 (en) A pharmaceutical composition containing N-phosphonoglycine derivatives for inhibiting the growth of viruses and cancers
Kokkinakis et al. Thresholds of O 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1, 3-bis (2-chloroethyl)-1-nitrosourea or temozolomide
US5731304A (en) Potentiation of temozolomide in human tumour cells
US6906091B2 (en) Method of cancer treatment
KR19990036138A (ko) 암 성장을 억제하기 위한 플루코나졸의 용도
WO2002045717A1 (en) Lometrexol combination therapy
MXPA98000998A (en) Use of fluconazole to inhibit the growth of cance
JPH11511136A (ja) 癌の成長を阻害するためのグリセオフルビンの使用
CN107683139A (zh) 用于治疗b细胞恶性肿瘤的赛度替尼
KR19990036136A (ko) 암 성장을 억제하기 위한 1h-1,2,4-트리아졸 유도체의 용도
MXPA98000944A (es) Uso de derivados de 1h-1,2,4-triazol para inhibirel crecimiento de canceres
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
US6638914B1 (en) Pharmaceutical administration of adenosine agonists
Rivera et al. Phase I clinical and pharmacokinetic study of 4′-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
AU721950B2 (en) Potentiation of temozolomide in human tumour cells
Cussac et al. Enhancement by O6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea antitumor action in chloroethylnitrosourea-resistant human malignant melanocytes.
EP2711009A1 (en) Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
Dhingra et al. Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor
HUP9903555A2 (en) Pharmaceutical compositions for inhibiting the growth of cancers containing 1h-1,2,4-triazole derivatives and a chemoterapeutic agent, and the use of the s